The Clinical Applications of Five-Alpha Reductase Inhibitors

    April 2021 in “ Canadian Journal of Urology ”
    Kevin R. Loughlin
    Studysummary This review summarizes existing studies on 5-alpha reductase inhibitors, noting their effectiveness in reducing prostate volume and cancer risk but highlighting an increased risk of higher grade prostate cancer.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on pubmed.ncbi.nlm.nih.gov →
    Discuss this study in the Community →

    Related research 7

    1. Current Pharmacological Treatment for Male LUTS Due to BPH: Dutasteride or Finasteride? Current Drug Targets · 2015
    2. Long-Term Use of 5α-Reductase Inhibitors and the Risk of Male Breast Cancer Cancer Causes & Control · 2014
    3. Regarding Prostate-Specific Antigen: Let's Not Shoot the Messenger QJM · 2011
    4. Therapeutic Hotline: Treatment of Androgenic Alopecia with Finasteride May Result in High-Grade Prostate Cancer in Patients: Fact or Fiction? Dermatologic Therapy · 2010
    5. Finasteride for Prostatic Disease: An Updated and Comprehensive Review Expert opinion on drug metabolism & toxicology · 2008
    6. Role of 5 Alpha-Reductase Inhibitors in the Management of Prostate Cancer Clinical interventions in aging · 2006
    7. 5α-Reductase Inhibitors and Chemoprevention: The PCPT and Beyond European Urology Supplements · 2006